| Field | Specification |
|---|---|
| Target | |
| Alternative names | TGF-beta receptor type-2;TGFR-2;2.7.11.30;TGF-beta type II receptor;Transforming growth factor-beta receptor type II;TGF-beta receptor type II;TbetaR-II;TGFBR2; |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human TGF beta Receptor II |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Overview
This product is an anti-TGFBR2 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone ABFE-20; isotype Rabbit IgG; reactivity: Human. Reported application contexts include WB (as provided in the source record). Boster Bio Anti-TGF beta Receptor II TGFBR2 Rabbit Monoclonal Antibody catalog # M00759. Tested in WB application. This antibody reacts with Human.
Key elements and design rationale
- Target: TGFBR2 (TGF-beta receptor type-2).
- Antibody format: Monoclonal; clone ABFE-20; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
TGFBR2 (protein: T-cell surface glycoprotein CD4) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non- promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non- canonical, SMAD-independent TGF-beta signaling pathways. . Reported cellular localization context: Cell membrane ; Single-pass type I membrane protein . Tissue expression notes (as provided): Expressed in fetal brain and in adult brain, heart, small intestine and colon.
Research relevance and current trends
- Research context keywords from the source record include: Nuclear Signaling,Protein Phosphorylation,Ser/Thr Kinases,Signal Transduction,Signaling Pathway,Signaling Pathways,Stem Cells,Surface Molecules,TGF Beta.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
Workflow ideas (metafield): Validate TGFBR2 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect TGFBR2 expression by Western blot in cell or tissue lysates, Compare relative TGFBR2 levels across experimental conditions (dose/time-course) using antibody-based readouts
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 20 kDa; calculated MW: 64568 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 20 kDa
- Cellular localization (provided): Cell membrane ; Single-pass type I membrane protein .
- Tissue details (provided): Expressed in fetal brain and in adult brain, heart, small intestine and colon.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
